{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:54Z","timestamp":1789014534629,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01923-3","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T12:06:07Z","timestamp":1652184367000},"page":"692-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase\u00a03 Trials"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct02828020","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02867709","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02873221","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrew M.","family":"Blumenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Knievel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Manack Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Severt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"1923_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-physiol-030212-183717","volume":"75","author":"D Pietrobon","year":"2013","unstructured":"Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365\u201391.","journal-title":"Annu Rev Physiol"},{"key":"1923_CR2","unstructured":"World Health Organization. Headache disorders. Geneva, Switzerland: World Health Organization. 2016. http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/headache-disorders. Accessed 9 Sept 2020."},{"issue":"5","key":"1923_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"key":"1923_CR4","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"7","key":"1923_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1526-4610.1995.hed3507387.x","volume":"35","author":"SD Silberstein","year":"1995","unstructured":"Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35(7):387\u201396.","journal-title":"Headache"},{"issue":"4","key":"1923_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ncl.2019.07.008","volume":"37","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Holland PR. An update: pathophysiology of migraine. Neurol Clin. 2019;37(4):651\u201371.","journal-title":"Neurol Clin"},{"issue":"1","key":"1923_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"key":"1923_CR8","doi-asserted-by":"crossref","unstructured":"Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973\u201389.","DOI":"10.1212\/CON.0000000000000199"},{"issue":"7","key":"1923_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14656566.2020.1721462","volume":"21","author":"M Curto","year":"2020","unstructured":"Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;21(7):755\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 3","key":"1923_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/head.13375","volume":"58","author":"E Loder","year":"2018","unstructured":"Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache. 2018;58(Suppl 3):218\u201329.","journal-title":"Headache"},{"key":"1923_CR11","unstructured":"Ubrelvy [package insert]. Madison, NJ: Allergan USA, Inc. 2020."},{"issue":"1","key":"1923_CR12","first-page":"160","volume":"373","author":"E Moore","year":"2020","unstructured":"Moore E, Fraley ME, Bell IM, et al. Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2020;373(1):160\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1 suppl","key":"1923_CR13","first-page":"S8","volume":"69","author":"AM Blumenfeld","year":"2020","unstructured":"Blumenfeld AM, Edvinsson L, Jakate A, Banerjee P. Pharmacology and pharmacokinetics of ubrogepant: a potent, selective calcitonin gene-related peptide receptor antagonist for the acute treatment of migraine. J Fam Pract. 2020;69(1 suppl):S8\u201312.","journal-title":"J Fam Pract"},{"issue":"1","key":"1923_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","volume":"20","author":"TP Do","year":"2019","unstructured":"Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.","journal-title":"J Headache Pain"},{"issue":"1","key":"1923_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-019-1027-7","volume":"20","author":"C Piccinni","year":"2019","unstructured":"Piccinni C, Cevoli S, Ronconi G, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20(1):74.","journal-title":"J Headache Pain"},{"issue":"8","key":"1923_CR16","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300\u201311.","journal-title":"Headache"},{"issue":"10","key":"1923_CR17","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/head.13642","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Hutchinson S, Ailani J, et al. Discontinuation of acute prescription medication for migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(10):1762\u201372.","journal-title":"Headache"},{"issue":"7","key":"1923_CR18","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/head.12404","volume":"54","author":"AJ Messali","year":"2014","unstructured":"Messali AJ, Yang M, Gillard P, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54(7):1120\u201330.","journal-title":"Headache"},{"issue":"23","key":"1923_CR19","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341.","journal-title":"N Engl J Med"},{"issue":"19","key":"1923_CR20","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant versus placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE\u00a0II randomized clinical trial. JAMA. 2019;322(19):1887\u201398.","journal-title":"JAMA"},{"issue":"1","key":"1923_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/head.13682","volume":"60","author":"J Ailani","year":"2020","unstructured":"Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020;60(1):141\u201352.","journal-title":"Headache"},{"issue":"1","key":"1923_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-019-1032-x","volume":"20","author":"LS Loo","year":"2019","unstructured":"Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.","journal-title":"J Headache Pain"},{"issue":"4","key":"1923_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1517\/17425255.2016.1154042","volume":"12","author":"L Lionetto","year":"2016","unstructured":"Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12(4):399\u2013406.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"1923_CR24","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/head.12864","volume":"56","author":"H Ansari","year":"2016","unstructured":"Ansari H, Ziad S. Drug-drug interactions in headache medicine. Headache. 2016;56(7):1241\u20138.","journal-title":"Headache"},{"issue":"1","key":"1923_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-019-1010-3","volume":"20","author":"LM Pomes","year":"2019","unstructured":"Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20(1):56.","journal-title":"J Headache Pain"},{"issue":"8","key":"1923_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","volume":"2","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta D, Sahoo AK. Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med. 2020;2(8):1132\u20138.","journal-title":"SN Compr Clin Med"},{"key":"1923_CR27","unstructured":"Topamax [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2019."},{"issue":"4","key":"1923_CR28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","volume":"61","author":"A Jakate","year":"2021","unstructured":"Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642\u201352.","journal-title":"Headache"},{"key":"1923_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/2515816320905082","author":"C Li","year":"2020","unstructured":"Li C, Palcza J, Xu J, et al. The effect of multiple doses of ubrogepant on the pharmacokinetics of an oral contraceptive in healthy women: results of an open-label, single-center, two-period, fixed-sequence study. Cephalalgia Rep. 2020. https:\/\/doi.org\/10.1177\/2515816320905082.","journal-title":"Cephalalgia Rep."},{"key":"1923_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/2515816320921186","author":"A Jakate","year":"2020","unstructured":"Jakate A, Boinpally R, Butler M, et al. Evaluation of the pharmacokinetic interaction and safety of ubrogepant coadministered with acetaminophen or nonsteroidal anti-inflammatory drugs: a randomized trial. Cephalalgia Rep. 2020. https:\/\/doi.org\/10.1177\/2515816320921186.","journal-title":"Cephalalgia Rep."},{"key":"1923_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102420938652","volume":"40","author":"E Navratilova","year":"2020","unstructured":"Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. 2020;40:892\u2013902.","journal-title":"Cephalalgia"},{"key":"1923_CR32","unstructured":"Aimovig [package insert]. Thousand Oaks, CA, and East Hanover, NJ: Amgen Inc., and Novartis Pharmaceuticals Corporation; 2020."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01923-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01923-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01923-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T09:06:55Z","timestamp":1700557615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01923-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1923"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01923-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}